PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34729938-6	2021	Long-term exposure to crizotinib could decrease the sensitivity of ALK+ NSCLC cells to crizotinib via increasing the levels of glycolysis related to hexokinases II (HK2).	Crizotinib	22-32	hexokinase 2	Homo sapiens	165-168	
34729938-6	2021	Long-term exposure to crizotinib could decrease the sensitivity of ALK+ NSCLC cells to crizotinib via increasing the levels of glycolysis related to hexokinases II (HK2).	Crizotinib	87-97	hexokinase 2	Homo sapiens	165-168	
34729938-8	2021	2DG sensitization crizotinib might be associated with the inhibition of HK2-mediated glycolysis and P-ALK/AKT/mTOR signaling pathway in H3122 and H2228 cells.	Crizotinib	18-28	hexokinase 2	Homo sapiens	72-75	
34729938-9	2021	CONCLUSIONS: These results indicate that HK2-mediated glycolysis plays a crucial role in the increased tolerance of ALK+ NSCLC cells to crizotinib.	Crizotinib	136-146	hexokinase 2	Homo sapiens	41-44	
34729938-10	2021	2DG may sensitize ALK+ NSCLC to crizotinib via suppression of HK2-mediated glycolysis and the AKT/mTOR signaling pathway.	Crizotinib	32-42	hexokinase 2	Homo sapiens	62-65